Centessa Pharmaceuticals Reveals Promising Phase 1 Data

Grafa

2024-09-10

Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.

Centessa shares jumped 14% in premarket trading.

The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.

Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).

“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2466360944"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466360944\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2466360944?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466360944","market":"us","top_or_hot":-1,"title":"Centessa Pharmaceuticals Reveals Promising Phase 1 Data","media":"Grafa","content":"<html><head></head><body><p class=\"t-img-caption\"><img alt=\"\" src=\"https://community-static.tradeup.com/news/a7b50cbda539c1b6af1546dc80d094b6\" tg-height=\"1080\" tg-width=\"1920\" title=\"\"/></p><p>Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.</p><p>Centessa shares jumped 14% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b9f2d45559333346ba1926ee3f72b6e2\" tg-height=\"840\" tg-width=\"790\"/></p><p>The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.</p><p>Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).</p><p>“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.</p><p>The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.</p><p> </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Centessa Pharmaceuticals Reveals Promising Phase 1 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals Reveals Promising Phase 1 Data\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1019687050\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Grafa </p>\n<p class=\"h-time smaller\">2024-09-10 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p class=\"t-img-caption\"><img alt=\"\" src=\"https://community-static.tradeup.com/news/a7b50cbda539c1b6af1546dc80d094b6\" tg-height=\"1080\" tg-width=\"1920\" title=\"\"/></p><p>Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.</p><p>Centessa shares jumped 14% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b9f2d45559333346ba1926ee3f72b6e2\" tg-height=\"840\" tg-width=\"790\"/></p><p>The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.</p><p>Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).</p><p>“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.</p><p>The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.</p><p> </p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTA","symbol_name":"Centessa Pharmaceuticals plc","start_time":0,"source_url":"https://grafa.com/news/health-centessa-pharmaceuticals-reveals-promising-phase-1-data-273036?referralcode=A314DFDBE96C354756A893C6E3E02493","article_id":"2466360944","we_media_id":"1019687050","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466360944","pubTimestamp":1725969713,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Grafa","introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks as well as forex, crypto and economic news. News is generated in near real-time due to Grafa's unique data-led approach to media content generation.","home_visible":1,"id":"1019687050","head_image":"https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15"},"summary":"Centessa Pharmaceuticals  has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2  agonist, ORX750.The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo .“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTA":"Centessa Pharmaceuticals plc"},"translate_title":"Centessa Pharmaceuticals公布了有希望的一期数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":1.1},"content_text":"Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.Centessa shares jumped 14% in premarket trading.The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0}}}